My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 506285 | NSE: BAYERCROP | Pesticides & Agrochemicals | Small Cap
1. Is Bayer CropScience Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Bayer CropScience Ltd is a good quality company.
2. Is Bayer CropScience Ltd undervalued or overvalued?
The key valuation ratios of Bayer CropScience Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Bayer CropScience Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Bayer CropScience Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 16.2% | 20.6% | 16.8% | 15.3% | 16.3% | 17.4% | 23.7% | 19.1% | 23.9% | 26.5% | - | ||
| Value Creation Index ⓘ | 0.2 | 0.5 | 0.2 | 0.1 | 0.2 | 0.3 | 0.8 | 0.7 | 0.8 | 1.0 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 3,245 | 3,723 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,377 | ||
| YoY Gr. Rt. % | - | 14.7% | -25.6% | 1.2% | -3.3% | 16.9% | 14% | 18.1% | 11.1% | 8.6% | - | ||
| Adj EPS ⓘ | 80.2 | 105.2 | 89.8 | 83.2 | 88.5 | 99.7 | 124.9 | 106.8 | 133.1 | 150.8 | 187.9 | ||
| YoY Gr. Rt. % | - | 31.1% | -14.6% | -7.4% | 6.4% | 12.6% | 25.3% | -14.5% | 24.7% | 13.3% | - | ||
| BVPS (₹) ⓘ | 476 | 555.4 | 519.6 | 581 | 518.5 | 649.8 | 572.9 | 568 | 562.2 | 604 | 696.8 | ||
| Adj Net Profit ⓘ | 294 | 385 | 317 | 294 | 304 | 342 | 561 | 480 | 598 | 678 | 844 | ||
| Cash Flow from Ops. ⓘ | 282 | 200 | 207 | 157 | 121 | 433 | 666 | 687 | 216 | 609 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 5.2% | 13.7% | 12.5% | 8.6% | ||||||||
| Adj EPS ⓘ | 7.3% | 11.3% | 6.5% | 13.3% | ||||||||
| BVPSⓘ | 2.7% | 3.1% | 1.8% | 7.4% | ||||||||
| Share Price | 12.4% | 4.7% | 2.2% | 16.6% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 16 | 20.4 | 16.4 | 15.1 | 15.8 | 17 | 23.3 | 18.7 | 23.6 | 25.9 | 28.9 | |
| Op. Profit Mgn % ⓘ | 12.7 | 13.9 | 15.8 | 14.9 | 15.3 | 15.4 | 20.2 | 19 | 17.1 | 17.9 | 19 | |
| Net Profit Mgn % ⓘ | 9.1 | 10.3 | 11.5 | 10.5 | 11.2 | 10.8 | 15.6 | 11.3 | 12.6 | 13.2 | 15.7 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Working Cap Days ⓘ | 244 | 238 | 326 | 357 | 439 | 411 | 389 | 345 | 349 | 359 | 248 | |
| Cash Conv. Cycle ⓘ | 63 | 65 | 101 | 110 | 131 | 101 | 81 | 74 | 77 | 87 | 139 | |
Return on Equity has increased versus last 3 years average to 28.90%
Sales growth is growing at healthy rate in last 3 years 12.50%
Net Profit has been subdued in last 3 years 6.48%
Sales growth is not so good in last 4 quarters at 5.64%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 187.9 | 12.3 |
| TTM Sales (₹ Cr.) | 5,377 | 783 |
| BVPS (₹.) ⓘ | 696.8 | 0 |
| Reserves (₹ Cr.) ⓘ | 3,087 | 294 |
| P/BV ⓘ | 7.71 | 0.00 |
| PE ⓘ | 28.61 | 436.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 3922.45 / 5619.00 |
| All Time Low / High (₹) | 34.13 / 6550.00 |
| Market Cap (₹ Cr.) | 24,158 |
| Equity (₹ Cr.) | 44.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 34.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Bayer CropScience is the flagship company of the Bayer Group in India and is publicly listed on the Bombay Stock Exchange. It is engaged in manufacturing of crop protection products, non agricultural pest-control, seeds and plant biotechnology. The company enjoys a unique position in the market because of its capability to offer new innovative products, technologies, processes, services and business models. With its innovative products, it is contributing to finding solutions to some of the major challenges of its time. The company remains committed to improving lives by advancing nutrition and healthcare solutions for the country’s growing population.
Business area of the company
The company’s Crop Science division is the largest for Bayer in India with businesses in seeds & traits, crop protection, digital farming and environmental science (non-agricultural pest control). Its robust crop protection portfolio includes products to manage insects, pests, weeds and diseases. It also includes bilogical solutions, that use nature’s own defenses to protect crops. Its broad range of high-quality hybrid seeds includes cutting-edge traits for high-yielding crops with improved weed management and superior insect control. Its expertise and innovations in digital farming provide farmers with a deeper understanding of their fields so they can utilize their inputs and natural resources as efficiently as possible. The company also has products that focus on non-agricultural applications in the form of products and services for vector control and professional pest control.
The company’s Pharmaceuticals division in India operates as Bayer Zydus Pharma, a joint venture between Bayer and Zydus Cadila. The focus of this business is on prescription products, especially for cardiology and women’s health care and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents. Its Consumer Health division is focused on making self-care for a better life a reality for billions of people around the world through everyday healthcare. Its Animal Health business develops and markets products and solutions for the prevention and treatment of diseases in companion and farm animals.
Awards:
Milestones:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
